GT Biopharma Narrows Losses, Raises Capital Amid Going Concern Doubts

Ticker: GTBP · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 109657

Sentiment: mixed

Topics: Biotechnology, Clinical Stage, Immuno-oncology, Going Concern, R&D Spending, Capital Raise, Net Loss

TL;DR

**GTBP is burning less cash and raising capital, but the 'going concern' warning still screams high risk for this pre-revenue biotech.**

AI Summary

GT Biopharma, Inc. reported a net loss of $2.2 million for the six months ended June 30, 2025, a significant improvement from the $5.98 million net loss in the same period of 2024. The company generated no revenue in either period. Operating expenses decreased substantially, with research and development falling from $2.56 million in H1 2024 to $1.46 million in H1 2025, and selling, general and administrative expenses dropping from $4.44 million to $1.98 million. Cash used in operating activities decreased from $7.7 million in H1 2024 to $5.22 million in H1 2025. The company's cash and cash equivalents increased to $5.23 million as of June 30, 2025, up from $3.95 million at December 31, 2024, primarily due to $6.49 million in financing activities, including proceeds from Series L convertible preferred stock and warrants. Despite these improvements, the company's accumulated deficit reached $697.52 million, and management continues to raise substantial doubt about its ability to continue as a going concern.

Why It Matters

This filing is critical for investors as GTBP, a clinical-stage biopharmaceutical company, continues to operate without revenue, relying heavily on financing activities to sustain operations. The significant reduction in net loss and operating expenses, coupled with successful capital raises, could signal improved financial management and a longer runway for its TriKE and Dual Targeting TriKE platforms. However, the persistent 'going concern' warning from both management and auditors highlights the inherent risks in early-stage biotech, where clinical success and commercialization remain distant. Competitors in the immune-oncology space are well-funded, making GTBP's ability to secure continuous financing and advance its pipeline paramount to its survival and potential market impact.

Risk Assessment

Risk Level: high — The company explicitly states, 'These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued.' This is further supported by an accumulated deficit of $697.52 million and continued operating losses, despite a reduction in net loss.

Analyst Insight

Investors should approach GTBP with extreme caution, recognizing it as a highly speculative investment. While the reduction in net loss and successful capital raises are positive, the fundamental 'going concern' risk means the company's long-term viability is uncertain. Monitor future financing activities and clinical trial progress closely, as these will be key determinants of its survival.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$2.2M
eps
N/A
gross Margin
N/A
cash Position
$5.23M
revenue Growth
0.0%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$00.0%

Key Numbers

Key Players & Entities

FAQ

What is GT Biopharma's current financial position regarding revenue and net income?

GT Biopharma, Inc. reported no revenue for the six months ended June 30, 2025, or the comparable period in 2024. The company's net loss for the six months ended June 30, 2025, was $2.2 million, a significant improvement from the $5.98 million net loss reported for the same period in 2024.

What are the key changes in GT Biopharma's operating expenses?

For the six months ended June 30, 2025, GT Biopharma's research and development expenses decreased to $1.46 million from $2.56 million in the prior year. Selling, general and administrative expenses also saw a substantial reduction, falling to $1.98 million from $4.44 million in the same period of 2024.

How has GT Biopharma's cash position changed?

GT Biopharma's cash and cash equivalents increased to $5.23 million as of June 30, 2025, up from $3.95 million at December 31, 2024. This increase was primarily driven by $6.49 million in net cash provided by financing activities during the six-month period.

What is the significance of the 'going concern' warning for GT Biopharma?

The 'going concern' warning indicates that GT Biopharma's management and independent auditors have substantial doubt about the company's ability to continue operations for at least one year. This is due to sustained operating losses, an accumulated deficit of $697.52 million, and the absence of product revenue, highlighting a critical need for ongoing financing.

What are GT Biopharma's primary product platforms?

GT Biopharma is focused on developing novel immune-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. These platforms are designed to harness and enhance the cancer-killing abilities of a patient's natural killer cells (NK cells).

How does GT Biopharma typically finance its operations?

Historically, GT Biopharma has financed its operations through public and private sales of common stock, the issuance of preferred and common stock, the issuance of convertible debt instruments, and strategic collaborations. For the six months ended June 30, 2025, the company raised $5.44 million from the issuance of Series L convertible preferred stock and warrants.

What is GT Biopharma's accumulated deficit?

As of June 30, 2025, GT Biopharma's accumulated deficit stood at $697.52 million. This substantial deficit reflects the company's history of operating losses since its inception as a clinical-stage biopharmaceutical company.

What non-cash activities did GT Biopharma report?

Significant non-cash activities for the six months ended June 30, 2025, included the fair value of vested warrants issued in Series L convertible preferred stock transactions totaling $3.39 million, and the fair value of prefunded warrants issued for an ELOC fee of $672,000. Additionally, $847,000 in prefunded warrants or common stock were issued to settle vendor payables.

What is the company's current number of common shares outstanding?

As of August 8, 2025, GT Biopharma had 3,557,502 shares of common stock outstanding. This represents an increase from 2,234,328 shares outstanding as of December 31, 2024.

Where is GT Biopharma's principal executive office located?

Effective July 1, 2024, GT Biopharma became a fully remote company and does not maintain a principal executive office. For stockholder communications, the company directs mail to 505 Montgomery Street, 10th Floor, San Francisco, California 94111, or by email to auditcommittee@gtbiopharma.com.

Risk Factors

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like GT Biopharma often operate at a loss for extended periods, relying on external funding until a product gains regulatory approval and market traction. The competitive landscape is intense, with many companies vying for funding and market share.

Regulatory Implications

As a biopharmaceutical company, GT Biopharma is subject to stringent regulations from bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or changes in regulatory policy can significantly impact development timelines and the potential for commercialization, posing a substantial risk.

What Investors Should Do

  1. Monitor future financing rounds closely: Given the ongoing going concern issues and lack of revenue, investors should scrutinize any new equity or debt issuances for dilution and terms.
  2. Evaluate R&D progress: Investors need to assess the company's pipeline development and clinical trial progress to gauge future revenue potential, despite current cost reductions.
  3. Assess cash burn rate: While cash used in operations has decreased, it remains substantial. Investors should track the burn rate against the current cash position to estimate runway.
  4. Understand the going concern implications: Investors must consider the significant risk associated with the company's ability to continue as a going concern when making investment decisions.

Glossary

Accumulated Deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total amount of money a company has lost over its lifetime. (Indicates GT Biopharma's long-standing inability to generate profits, reaching $697.52 million as of June 30, 2025.)
Going Concern
A business's ability to continue operating for the foreseeable future without the threat of liquidation. Auditors assess this, and if doubt exists, it must be disclosed. (Management's statement raises substantial doubt about GT Biopharma's ability to continue operating, a critical warning for investors.)
Financing Activities
Cash flows related to transactions involving debt, equity, and dividends. This section of the cash flow statement shows how a company raises and repays capital. (GT Biopharma relied heavily on financing activities ($6.49 million) to increase its cash reserves, highlighting a lack of operational cash generation.)
Convertible Preferred Stock
A class of preferred stock that can be converted into a specified number of common stock shares at certain times. (Proceeds from Series L convertible preferred stock contributed to the company's cash balance, a common funding mechanism for early-stage companies.)

Year-Over-Year Comparison

GT Biopharma has shown a significant improvement in its net loss for the first half of 2025 compared to 2024, reducing it from $5.98 million to $2.2 million. This was driven by substantial reductions in both R&D and SG&A expenses, leading to a lower cash burn from operations. However, the company continues to generate no revenue, and its accumulated deficit has grown, reinforcing the going concern warning.

Filing Stats: 4,555 words · 18 min read · ~15 pages · Grade level 16.9 · Accepted 2025-08-14 16:01:14

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 31 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 32

SIGNATURES

SIGNATURES 33 2 GT BIOPHARMA, INC. Condensed Balance Sheets June 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 5,228,000 $ 3,951,000 Restricted cash 93,000 93,000 Deferred offering costs 760,000 — Prepaid expenses and other current assets 1,043,000 188,000 TOTAL ASSETS $ 7,124,000 $ 4,232,000 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable $ 1,374,000 $ 3,853,000 Accrued expenses 608,000 1,797,000 Dividend payable 85,000 — Warrant liability 240,000 252,000 Total Current Liabilities 2,307,000 5,902,000 Mezzanine Equity Convertible Preferred stock, par value $ 0.01 , 15,000,000 shares authorized Series L - 6,301 and 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 1,956,000 — Stockholders' Equity (Deficit) Convertible Preferred stock, par value $ 0.01 , 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 1,000 1,000 Common stock, par value $ 0.001 , 250,000,000 shares authorized, 3,272,995 and 2,234,328 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 3,000 2,000 Additional paid in capital 700,378,000 693,554,000 Accumulated deficit ( 697,521,000 ) ( 695,227,000 ) Total Stockholders' Equity (Deficit) 2,861,000 ( 1,670,000 ) TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' (EQUITY) DEFICIT $ 7,124,000 $ 4,232,000 The accompanying notes are an integral part of these unaudited condensed financial statements. 3 GT BIOPHARMA, INC. Condensed 2025 2024 2025 2024 The Three Months For the Six Months Ended June 30, Ended June 30, 2025 2024 2025 2024 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Revenues $ — $ — $ — $ — Operating Expenses: Research and development $ 363,000 $

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing